Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Aktis Oncology Partners with Lilly to Advance Novel Anticancer Radiopharmaceuticals

NextEdge Admin

22 May 2024

2 min 32 sec

Radiopharmaceuticals,Diagnostic,therapeutic

Aktis Oncology, a pioneering biotechnology firm, has forged a strategic collaboration with Eli Lilly and Company, a leading player in oncology drug development. The partnership aims to harness Aktis’ innovative miniprotein technology platform to create groundbreaking radiopharmaceuticals for combating a wide spectrum of solid tumors.

Matthew Roden, Aktis Oncology’s President and CEO, emphasized the alliance’s significance in leveraging their miniprotein radiopharmaceutical platform to target novel cancer markers effectively. He expressed optimism about expanding patient access to impactful radiopharmaceutical treatments through this collaboration.

Under the terms of the agreement, Aktis will receive a substantial $60 million upfront cash payment along with an equity investment from Lilly. Additionally, Aktis stands to gain up to $1.1 billion in potential milestones across various stages of development and commercialization, along with tiered royalties.

In return, Lilly secures global rights to develop radiopharmaceutical therapeutic and diagnostic products based on targets discovered by Aktis. Jacob Van Naarden, Lilly Oncology’s President, highlighted the strategic value of incorporating Aktis’ technology into their radiopharmaceutical capabilities to advance innovative cancer therapies.

Aktis Oncology, incubated by MPM Capital, specializes in developing targeted alpha radiopharmaceuticals for solid tumors. Their lead program targets Nectin-4, a tumor-associated antigen prevalent in urothelial and other cancers. These molecules, designed for optimal tumor penetration and minimal off-target effects, promise enhanced efficacy while minimizing treatment-related side effects.

The company’s approach facilitates visualization and verification of target engagement before therapeutic radioisotope exposure, ensuring precise treatment delivery. This collaboration underscores Aktis Oncology’s commitment to advancing next-generation radiopharmaceuticals for the benefit of cancer patients worldwide.